Profile data is unavailable for this security.
About the company
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
- Revenue in AUD (TTM)0.00
- Net income in AUD-42.32m
- Incorporated2010
- Employees--
- LocationClarity Pharmaceuticals Ltd4 Cornwallis Street, National Innovation Centre,EVELEIGH 2015AustraliaAUS
- Phone+61 29209-4037
- Websitehttps://www.claritypharmaceuticals.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polaris Group LLC | 3.09m | -90.11m | 1.78bn | -- | -- | 5.48 | -- | 575.07 | -2.57 | -2.57 | 0.0881 | 9.22 | 0.007 | -- | 33.03 | -- | -20.88 | -16.55 | -22.66 | -17.96 | -19.17 | -- | -2,973.29 | -12,960.21 | 9.74 | -- | 0.2065 | -- | 16.18 | -- | -37.05 | -- | 50.45 | -- |
| TYK Medicines Inc | 0.00 | -90.77m | 1.78bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Mabwell Shanghai Bioscience Co Ltd | 35.85m | -227.32m | 2.08bn | 1.40k | -- | 5.14 | -- | 58.14 | -2.69 | -2.69 | 0.424 | 4.80 | 0.0379 | 0.089 | 9.74 | 113,628.50 | -24.10 | -37.61 | -30.74 | -45.95 | 90.50 | 81.54 | -636.41 | -2,112.26 | 1.25 | -41.98 | 0.5339 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Bio-Thera Solutions Ltd | 174.62m | -79.92m | 2.12bn | 1.17k | -- | 11.83 | -- | 12.14 | -0.9121 | -0.9121 | 1.99 | 2.05 | 0.3533 | 1.00 | 6.83 | 707,092.40 | -16.17 | -23.62 | -26.76 | -30.81 | 69.81 | 79.76 | -45.77 | -106.72 | 0.716 | -27.47 | 0.4531 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 2.39bn | -- | -- | 15.89 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Keymed Biosciences Inc | 17.32m | -157.61m | 2.41bn | 1.12k | -- | 4.30 | -- | 138.90 | -3.06 | -3.06 | 0.3366 | 10.16 | 0.0207 | 0.3115 | 7.74 | 98,116.83 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 191.53m | -76.42m | 2.74bn | 574.00 | -- | 16.84 | -- | 14.31 | -1.34 | -1.34 | 3.35 | 2.63 | 0.2998 | 3.49 | 2.19 | 1,669,540.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Joinn Laboratories China Co Ltd | 449.59m | -193.18k | 2.87bn | 2.59k | -- | 1.84 | -- | 6.39 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| InnoCare Pharma Ltd | 190.23m | -79.46m | 3.01bn | 1.09k | -- | 3.71 | -- | 15.81 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Argo Investments Ltd. (Investment Management)as of 06 Sep 2024 | 9.80m | 3.10% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.59m | 3.03% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 4.78m | 1.51% |
| BlackRock Fund Advisorsas of 02 Oct 2024 | 2.21m | 0.70% |
| Pengana Capital Ltd.as of 28 Jun 2024 | 1.99m | 0.63% |
| Platinum Investment Management Ltd.as of 31 Aug 2024 | 1.30m | 0.41% |
| Investors Mutual Ltd.as of 30 Sep 2024 | 732.51k | 0.23% |
| BetaShares Capital Ltd.as of 30 Sep 2024 | 658.27k | 0.21% |
| Charles Schwab Investment Management, Inc.as of 03 Oct 2024 | 518.83k | 0.16% |
| Antares Capital Partners Ltd.as of 31 Aug 2024 | 470.59k | 0.15% |
